Live Breaking News & Updates on Lexicon Pharmaceuticals Trading
Stay updated with breaking news from Lexicon pharmaceuticals trading. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Reaffirmed by Needham & Company LLC theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Lexicon Pharmaceuticals (NASDAQ:LXRX) Rating Increased to Sell at StockNews.com themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by research analysts at Leerink Partnrs in a note issued to investors on Tuesday, Zacks.com reports. Leerink Partnrs also issued estimates for Lexicon Pharmaceuticals’ Q1 2024 earnings at ($0.13) EPS, Q2 2024 earnings at ($0.13) EPS, Q3 2024 earnings at ($0.13) EPS, […] ....
Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by investment analysts at Leerink Partnrs in a report issued on Tuesday, Zacks.com reports. Leerink Partnrs also issued estimates for Lexicon Pharmaceuticals’ Q1 2024 earnings at ($0.13) EPS, Q2 2024 earnings at ($0.13) EPS, Q3 2024 earnings at ($0.13) EPS, Q4 2024 […] ....
Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report)‘s stock had its “outperform” rating reissued by equities research analysts at Leerink Partnrs in a report released on Tuesday, Zacks.com reports. Leerink Partnrs also issued estimates for Lexicon Pharmaceuticals’ Q1 2024 earnings at ($0.13) EPS, Q2 2024 earnings at ($0.13) EPS, Q3 2024 earnings at ($0.13) EPS, Q4 […] ....